Skip to main content
Clinical Trials/NL-OMON38184
NL-OMON38184
Completed
Phase 3

Pharmacological Treatment in Hand Osteoarthritis - FABIO

Maasstadziekenhuis0 sites200 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
gewrichtaandoening
Sponsor
Maasstadziekenhuis
Enrollment
200
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional

Investigators

Sponsor
Maasstadziekenhuis

Eligibility Criteria

Inclusion Criteria

  • Age \* 40 years
  • Primary hand OA according to the ACR classification
  • Heberden or Bouchard nodule or Kellgren\-Lawrence grade 1, 2 or 3 in \* 2 symptomatic joints
  • Pain in the dominant hand \* 12 months
  • Use of an NSAID for \* 1 episode of pain
  • Written informed consent

Exclusion Criteria

  • Secondary hand OA, e.g. hemochromatose, rheumatoid arthritis, posttraumatic
  • Kellgren\-Lawrence grade 4 OA
  • Use of hydroxychloroquine within 3 months before entering the study
  • Use of NSAIDs or corticosteroids within 7 days before entering the study
  • Retinopathy
  • Myastenia Gravis
  • Known allergy or hypersensitivity for hydroxychloroquine

Outcomes

Primary Outcomes

Not specified

Similar Trials